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Summary
Neurofibromatosis type 1 (NF1), a common autosomal
dominant disorder caused by mutations of theNF1 gene,
is characterized by multiple neurofibromas, pigmenta-
tion anomalies, and a variety of other possible compli-
cations, including an increased risk of malignant neo-
plasias. Tumorigenesis in NF1 is believed to follow the
two-hit hypothesis postulated for tumor-suppressor
genes. Loss of heterozygosity (LOH) has been shown to
occur in NF1-associatedmalignancies and in benign neu-
rofibromas, but only few of the latter yielded a positive
result. Here we describe a systematic approach of search-
ing for somatic inactivation of the NF1 gene in neuro-
fibromas. In the course of these studies, two new intra-
genic polymorphisms of the NF1 gene, a tetranucleotide
repeat and a 21-bp duplication, could be identified.
Three tumor-specific point mutations and two LOH
events were detected among seven neurofibromas from
four different NF1 patients. Our results suggest that
small subtle mutations occur with similar frequency to
that of LOH in benign neurofibromas and that somatic
inactivation of the NF1 gene is a general event in these
tumors. The spectrum of somatic mutations occurring
in various tumors from individual NF1 patients may
contribute to the understanding of variable expressivity
of the NF1 phenotype.
Introduction
Neurofibromatosis type 1 (NF1 [MIM 16220]) is an
autosomal dominant inherited disease that is character-
ized by the occurrence of multiple neurofibromas and
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pigmentation anomalies (e.g., cafe´ au lait macules and
Lisch nodules). Besides these diagnostic criteria for NF1,
a variety of complications may arise, including an in-
creased risk for certain malignancies. Another charac-
teristic feature of the disease is the high degree of variable
expressivity, which renders NF1 a model system for the
study of modifying effects on hereditary diseases. The
variable expressivity of the NF1 gene defects abrogates
the possibility of predicting patients’ outcomes. TheNF1
gene has been mapped to chromosome 17q11.2, and,
since its cloning in 1990, numerous constitutional mu-
tations of patients have been described (Upadhyaya and
Cooper 1998, NNFF International NF1 Genetic Mu-
tation Analysis Consortium, HumanGeneMutationDa-
tabase Cardiff). Point mutations, small insertions, and
deletions are randomly scattered throughout the gene,
with few positions where recurrent mutations have oc-
curred. Tumorigenesis in NF1 has been assumed to fol-
low the two-hit hypothesis for tumor-suppressor genes
that was initially postulated by Knudson for the reti-
noblastoma gene (Knudson 1971).
LOH has been shown for a number of NF1-associated
malignancies, as well as for malignant tumors or cell
lines thereof from non-NF1 patients (Xu et al. 1992;
Andersen et al. 1993; Johnson et al. 1993; Legius et al.
1993; Shannon et al. 1994). Recently, the somatic in-
activation of the NF1 gene has been described as oc-
curring in benign neurofibromas also (Colman et al.
1995; Sawada et al. 1996; Da¨schner et al. 1997; Serra
et al. 1997). One of these studies (Sawada et al. 1996)
described a short deletion occurring in neurofibroma
cells in a patient whose constitutional mutation was a
deletion of the wholeNF1 gene. These authors were also
able to show that only a subset of cells from the tumor
harbored the somatic event. The other studies concen-
trated on a more indirect approach to searching for LOH
in benign neurofibromas, but only few of these studies
yielded positive results. Editing of the NF1 mRNA has
also been discussed as playing a role in tumorigenesis in
NF1 (Cappione et al. 1997; Skuse and Cappione 1997).
The analysis of the spectrum of mutations occurring in
various neurofibromas of NF1 patients is an important
task, because the type and frequency of these mutations
could have an impact on the severity of patients’ phe-
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notypes, as has been postulated for other hereditary can-
cer syndromes, such as familial adenomatous polyposis
(Spirio et al. 1999). For the APC gene, the RB gene, and
other tumor-suppressor genes, databases of constutional
mutations and somatic mutations found in tumors have
been set up as a survey of mutated alleles occurring in
somatic and germ cells (APC Gene Database, RB1base).
So far, only germline mutations and polymorphisms of
the NF1 gene are included in the databases (NNFF In-
ternational NF1 Genetic Mutation Analysis Consor-
tium, Human Gene Mutation Database Cardiff). The
aim of our study was to start a systematic approach to
searching for somatic inactivation of the NF1 gene in
neurofibromas. For this purpose, neurofibromas were
screened for mutations causing premature translational
termination with the protein-truncation test. In cases
where no truncated peptide was found, tumor DNAwas
analyzed by LOH analysis with a series of polymorphic
markers, two of which are newly described in this paper,
in comparison to patients’ blood DNA. This is the first
description of a systematic search for somatic mutation
of the NF1 gene in neurofibromas from NF1 patients.
Material and Methods
Human Subjects
NF1 patients were diagnosed according to the criteria
of the NIH Consensus Statement (Stumpf et al. 1988).
An overview of the clinical data is given in table 1. Tu-
mors were wide and deep-excised after injection of li-
docaine. The two neurofibromas from patient NF260
were located on the abdomen, the neurofibromas from
patient NF282 were located in the central area of the
back, and the plexiform neurofibroma from patient
NF284 affected the sciatic nerve. Neither the precise lo-
cations nor the distances from each other of the excised
dermal tumors were documented by the surgeons.
Nucleic Acid Preparation from Tumor Specimen
Neurofibromas were kept in Dulbecco’s modified Ea-
gles medium (DMEM) until the tumor tissue was sep-
arated from the surrounding skin under careful visual
control. In some cases, the tumor tissue has been divided
into several pieces to raise cultures of fibroblast-like cells.
The other parts of the tumor or the tumor as a whole
and the skin were immediately shock-frozen in liquid
nitrogen and stored at 70C. Frozen tissues were ho-
mogenized with a bead mill (Mikrodismembrator II
Braun, Melsungen) before preparation either of total
RNA with the RNA-purification kit from Qiagen or
DNAwith the Qiaamp Tissue kit from the same supplier.
Both procedures were done according to the instructions
of the manufacturer.
Cultures of Fibroblast-Like Cells from Neurofibro-
mas.—Fresh tumor samples were minced into small
pieces and cells were disintegrated by treatment with
collagenase (1300 U) for 2 h. Cells were grown in
DMEM supplemented with 10% fetal-calf serum.
Reverse Transcription and PCR.—Two micrograms of
total RNA was reverse transcribed by random hexamer
priming with Superscript II reverse transcriptase (Gibco
BRL) in a final volume of 20 ml. PCR reactions contained
the after components: 2 ml cDNA, 10 mM Tris-HCl, pH
8.3, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.25
mM of forward and reverse primer, and 2.5 U Taq Poly-
merase (Amersham Pharmacia Biotech). All forward
primers for the protein truncation testing (PTT) ap-
proach included a leader sequence of a T7 transcription
promoter plus eukaryotic translation initiation signals.
Primer sequences for the PTT fragments were as follows;
the numbers give the position of the first 5′ and the last
3′ base of the fragments amplified with the respective
primers within the coding region of the neurofibromin
mRNA (NNFF International NF1 Genetic Mutation
Analysis Consortium). Leader: L=GGATCCTAATAC-
GACTCACTATAGGGAGACCACCATG; P1: L-1-
ATGGCCGCGCACAGGCCGGTGGAAT; P2: 1337-
GTTTCACCAAACATATTTCGAA; P3: L-967-GCCT-
GTGTCAAACTGTGTAAAG; P4: 1868-TGACAGGA-
ACTTCTATCTGCCTGCTTA; P5: L-1486-ATGGTG-
AAACTAATTCATGCAGAT; P6: 2675-CTGACA-
GGTGTATCTGCGTTT; P7: L-2308-ACTGCAGGA-
AACACTGAG; P8: 3583-TGTCAAATTCTGTGCC-
TTG; P9: L-3148-ATGGGAACATCAAACCAAGC;
P10: 4393-AATCAGATGCTATATCAAGGA; P11: L-
4024-ATGACTGAAAAGTTCTTCCATGC; P12:
5256-TAGGACTTTTGTTCGCTCTGCTGA; P13:
L-4998-GGAGTACACCAAGTATCATGAG; P14:
6282-CGGACCTGTGGCTACTAAGAA; P15: L-5902-
TACCCATCTATTCAATCAAA; P16: 6987-TATACG-
GAGACTATCTAAAGTATGCAG; P17: L-6574 ATG-
GAGGCATGCATGAGAGATATTC; P18: 7876-
TGGCCTCTGCTAAGTATTCATA; P19: L-7531-GCC-
AACACTAAGAAGTTGCTTG; and P20: 8404-TCT-
GCACTTGGCTTGCGGAT. The first rounds of PCR
reactions were done, for example, with primers 1 and
4; 0.5 ml of PCR products were then reamplified with
primers 1 and 2 as well as 3 and 4, and so on.
For LOH analyses, primers and PCR conditions were
used as published (Weber et al. 1990; Ainsworth and
Rodenhiser 1991; La´zaro et al. 1993a, 1993b, 1994;
Hoffmeyer and Assum 1994; Purandare et al. 1996). The
two newly identified polymorphisms locate to intron 1
(Pin1) and intron 28 (Pin28) of the NF1 gene. The
primer sequences for the new polymorphisms are as fol-
lows: Pin 1: CAGAGATTCTCCTCTCCTGCA, GAG-
TTCAACCTTTGAAGCCCA; Pin 28: TAGGTGTCC-
TACCCCTATAGT; AAAGGTCAAGAATCTTATAG-
AAG. For a few patients, it was possible to include the
Table 1
Summary of the Clinical Data of NF1 Patients, the Neurofibromas Analyzed, and the Mutations Identified by PTT or LOH
Patient, Sex Age, Family History, Phenotype
Previously Known
Constitutional
Mutation
Neurofibromas
Studied
Aberrant
PTT
Fragment Mutation Identifieda Protein Level LOH
NF56, F 58 years, sporadic, 1200 neurofibromas CrT position 1246 1, dermal None ) ) No
2, dermal None ) ) Yes
NF260, F 32 years, familiar, brain tumor, 1100 neurofibromas Unknown 1, dermal 5 TS: CrT position 3721 RrX position 1241 NA
2, dermal 6 TS: not identified NA
NF282, M 36 years, sporadic, 120 neurofibromas Unknown 1, dermal 1, 5 TS: CrT pos. 4021 QrX position 1341 NA
2, dermal 1, 5 TS: CrT pos. 4084 RrX position 1362 NA
C: GrA pos. 12601 11 altered amino acids, X at 428
13 bp IVS included (mRNA)
NF284, M 24 years, sporadic, skoliosis, 120 neurofibromas,
2 plexiform neurofibromas
Unknown 1, plexiform 6 C: 14-bp duplication,
position 4907–4920
40 altered amino acids, X at 1676 Yes
NOTE.—NA = not analyzed.
a C = constitutional; TS = tumor-specific.
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Figure 1 Distribution of PTT fragments over the coding region of the NF1 gene and relative position of premature stop codons that have
been found in neurofibromas. Constitutional mutations are italicized.
germline mutations in LOH analysis of the genomic
DNA isolated from blood and tumor specimen. In these
cases, the following intron-based primers were used:
PI8H: ACTTTTATCGGTATTTCTCAATATT; PI9R:
TTAGCAATACCTTTTGGACTAA; for NF56,
NFEx28H: TCTTTGTCTTTTTTGTCATTTTCC;
NFEx28R: AGTCAAGAAAAGCAATGAATCGT for
NF284.
Pin 1 was amplified at an annealing temperature of
62C for 30 cycles. The forward primer was labeled with
Cy5 and PCR products were run on the ALFexpress
DNA Sequencer (Amersham Pharmacia Biotech) for typ-
ing of alleles. PCR products range in size from 206–218
bps according to the number of repeated units present
in the alleles. The annealing temperature for the Pin 28
primers was 56C and PCR products (957 bps) were
digested with TaqI before agarose gel electrophoresis to
obtain a better resolution of the products from the dif-
ferent alleles (21 bp).
In Vitro Transcription and Translation.—PCR products
were exposed to the coupled transcription and transla-
tion reactions, as recommended by the supplier (Pro-
mega). For labeling of peptides, 35S-methionine (Amer-
sham Pharmacia Biotech) was included in the reactions.
Peptides were analyzed by Laemmli SDS-PAGE, and gels
were dried and exposed to X-ray films (Kodak X-Omat).
Reaction products derived from tumor specimen were
compared to products generated from fibroblast-like
cells from healthy individuals in each experiment.
Cloning and Sequence Analysis.—The purified PCR
products (PCR-Purification Kit [Qiagen]) were cloned in
Escherichia coli JM109 applying the Sure Clone Kit
(Amersham Pharmacia Biotech) as recommended by the
manufacturer. After the isolation of the plasmid DNA
with a commercially available kit (Amersham Pharmacia
Biotech), sequencing reactions were performed with the
Thermo Sequenase cycle sequencing Kit (Amersham
Pharmacia Biotech) and run on an ALFexpress DNA
Sequencer (Amersham Pharmacia Biotech).
Results
Search for NF1 Gene Mutations in Neurofibromas with
the Protein-Truncation Test
Seven tumors from four NF1 patients were included
in the screen for somatic mutations. Table 1 summarizes
the data for NF1 patients and tumors that were analyzed
by PTT. The constitutional NF1 mutation was already
known for one patient (NF56); the disease-causing mu-
tations of the other three patients were unknown at that
time, but two could be identified in the course of this
study. PTT analysis in neurofibromas was done with a
similar protocol to that used by Heim et al. (1995) in
their screening for constitutional mutations in NF1 pa-
tients. The whole coding region of the neurofibromin
gene was amplified in five overlapping RT-PCR frag-
ments. Whereas most of the neurofibroma samples did
not yield sufficient amounts of PCR product from these
large fragments for the subsequent steps of the reaction,
each fragment was further divided into two subfrag-
ments, each about 1 kb in size (fig. 1), and was ream-
plified in a nested PCR reaction (see PCR primers in
“Materials and Methods”).
Seven different shortened peptide fragments were de-
tected in the tumor samples. An overview of the position
of premature stop codons derived from fragments gen-
erated from the various neurofibromas is given in figure
1. Neurofibromas NF260-1 and NF260-2 revealed dif-
ferent altered PTT fragments; NF260-1 in fragment 5;
NF260-2 in fragment 6. Neurofibromas NF282-1 and
NF282-2 showed both an additional peptide of the same
size derived from fragment 1 and each of them harbored
a further aberrant peptide, compared to control cells in
fragment 5. The peptide bands in fragment 5 generated
from the two tumor samples were clearly different in
size and therefore should reflect different somatic mu-
tations in the neurofibromas of patient NF282, whereas
the common mutation in fragment 1 should represent
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Figure 2 Protein gel loaded with translation products of PTT
fragment 5 derived from various neurofibromas of NF1 patients and
cells of a healthy individual (C) NF260-1, NF282-1 andNF282-2 show
a truncated peptide derived from this part of the NF1 gene (arrows).
PTT analysis was done in duplicate for NF56-1 to show the repro-
ducibility of the peptide patterns.
the constitutional mutation. The last tumor that gave
positive results with the PTT was the plexiform neu-
rofibroma NF284-1, where an aberrant banding pattern
was found for peptides derived from fragment 6. The
result of a representative PTT-experiment is shown in
figure 2. All other neurofibromas did not show any al-
tered peptides compared to the pattern generated from
fibroblasts of healthy individuals. Tumors NF56-1 and
NF56-2 exhibited the additional band corresponding to
the already known constitutional mutation of patient
NF56.
The correspondingNF1 gene regions, assumed to har-
bor the causal sequence alterations, were reamplified
from the cDNA of neurofibromas with nested exon-
based PCR-primers, PCR-products were cloned inE. coli
and a number of recombinant plasmid clones were se-
quenced. In cases where we found alterations from the
NF1 cDNA sequence (M89914 [GenBank]), the pres-
ence of the mutation in the neurofibroma was first
checked by PCR with cDNA as template and modified
primers, that allowed to discriminate between the mu-
tant and the wild-type allele by restriction digestion. In
two cases (NF282 and NF284), the mutant and the wild-
type allele could be distinguished simply by an altered
size of the RT-PCR products (data not shown). All se-
quence variations initially identified at the cDNA-level
were also found in genomic DNA samples isolated either
from the corresponding neurofibromas in case of so-
matic mutations or from cultured fibroblast-like cells or
blood cells of the patients for constitutional mutations.
The details of the mutations that were identified are
summarized in table 1. Both tumors of patient NF282
exhibited the same GrA transition in position 12601,
which is the splice-donor site of intron 9. The mutation
leads to the inclusion of 13 bp of intervening sequence
into the NF1 messenger. The mutant allele is present in
all tissues tested from patient NF282 (as indicated by
an additional larger RT-PCR product or the presence of
an altered restriction site of the genomic PCR-products
by using modified intron-based primers; data not shown)
and is therefore assumed to represent the germline mu-
tation. NeurofibromaNF282-1 from this patient showed
an additional CrT transition at position 4021, neuro-
fibroma NF282-2 a further CrT transition at position
4084. Both alterations lead to premature stop codons in
the corresponding NF1 message.
The mutation of neurofibroma 1 from patient 260
(NF260-1) was a CrT transition at cDNA position
3721, resulting in a premature stop codon in the protein-
coding region of the NF1 gene. This mutation is specific
for the tumor NF260-1 and is not present in the other
tumor analyzed from this patient. The constitutional
mutation of this patient is still unknown and we did not
find any alterations that NF260-1 and NF260-2 had in
common. Tumor NF260-2 showed a truncated peptide
in fragment 6, but we were not able to find the under-
lying sequence alteration of this tumor after sequencing
of 110 recombinant plasmid clones. Possibly the mutant
allele was greatly underrepresented and therefore has
escaped detection.
The mutation that corresponds to the shorter peptide
generated from the plexiform neurofibroma NF284-1,
was a 14-bp duplication at cDNA position 4907, which
leads to a disruption of the reading frame and intro-
duction of a nearby stop codon (5027). This alteration
is not a tumor-specific event, because it turned out to be
present also in blood and cell cultures of patient NF284
and therefore represents the constitutional mutation. Al-
though we failed to identify a second mutational event
in this tumor, it exhibited LOH at the NF1-locus (see
next section).
Regarding the somatic point mutations, we can not
technically rule out the possibility that they may affect
the gene copy carrying the germline mutation. It is not
possible to link the somatic mutations with the regions
harboring the respective constitutional mutations, given
the fact that these mutations are too far away from each
other to be analyzed in common with our test system.
But, to us, this possibility seems rather unlikely, because
in this case the progenitor cells of the lesions should
have suffered from two independent somatic mutations
in both alleles of the NF1 gene, one affecting the con-
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Table 2
Summary of LOH Results with Polymorphic Markers of the Nf1 Gene Region Applied to Patients’ Blood and Tumor DNA
PATIENT AND
DNA SOURCE
STATUS AT
D17S33
5′ of NF1
Pin 1
NF1
Intron 1
RsaI
NF1
Exon 5
NF1
Mutation
Exon 9a
AluI
NF1
Intron 27b
284
NF1
Intron 27b
NF1
14-bp Dupl
Exon 28b
Pin 28
NF1
Intron 28
530
NF1
Intron 38
10647
NF1
3′UTR
Mfd 15
3′ of
NF1
NF56:
Blood NA H H H H NI NA H H H H
Neurofibroma 1 NA H H H H NI NA H H H H
Neurofibroma 2 NA LOH LOH LOH LOH NI NA LOH LOH LOH LOH
NF284:
Blood H NI NI NA NI NI H NI NI NI NI
Neurofibroma 1 H NI NI NA NI NI LOH NI NI NI NI
NOTE.—NA = not analyzed, NI = not informative, H = heterozygous, LOH = loss of heterozygosity.
a Specific for NF56.
b Specific for NF284.
stitutional mutant allele and another affecting the wild-
type allele.
LOH Analyses in Neurofibromas with Negative PTT
Results
The three neurofibromas with negative PTT results
(NF56-1, NF56-2 and NF284-1) were included in the
following investigations to search for loss of the wild-
type allele in tumor samples (table 2). Seven of the nine
genomic markers applied for this purpose are located in
the NF1 gene, whereas D17S33 and Mfd15 map prox-
imal and distal to the gene, respectively. The two re-
maining markers reflect specific constitutionalmutations
of the NF1 patients under investigation and therefore
were only tested with samples of the respective patient.
Pin 1 is a newly identified polymorphism (TGGA)n
located in intron 1, lying about 10 kb 5′ of exon 2 (I.
Eisenbarth, G. Assum, unpublished data). We found this
polymorphism by searching for small nucleotide repeats
in the GenBank clone AC004222, which comprises the
proximal end of the NF1 gene. The polymorphism re-
veals four frequent alleles with different numbers of the
four-nucleotide repetitive unit.
Pin 28, a polymorphism in intron 28 newly identified
in this study, is characterized by a 21-bp duplication.
Typing of 93 unrelated white individuals revealed allele
frequencies of .41 for the duplicated sequence and .59
for the nonduplicated sequence.
The genomic polymorphisms were partly analyzed by
PCR amplification with flanking intron-based primers
and subsequent acrylamide gel electrophoresis of the
products by using the ALFexpress DNA Sequencer
(Pin1, AluI, 28.4, 53.0, Mfd 15), the other markers were
analyzed by restriction digestion of amplification prod-
ucts and subsequent agarose gel electrophoresis
(D17S33, RsaI, Pin 28, 10647). Because the constitu-
tional mutations for the two patients (NF56 andNF284)
had already been identified, it was possible to design an
approach for both mutations that enabled discrimina-
tion between the NF1 allele carrying the constitutional
mutation and the wild-type allele.
For LOH analyses, the polymorphic markers were am-
plified in parallel from patients’ blood DNA and DNA
derived from neurofibromas. In each case, the amplifi-
cation patterns obtained from the tumor samples of the
patients were compared to the genotype of blood cells
from the patients.
An overview of the results is presented in table 2.
Tumor NF56-2 showed LOH with all informative ge-
nomic markers. Unequal allelic signal intensities were
obtained with each of these markers from DNA of this
tumor, whereas DNA from blood and from tumor
NF56-1 yielded bands of equal intensities. By use of the
constitutional mutation of patient NF56, we were able
to show that the PCR product with the weaker signal
intensity in NF56-2 derives from the wild-type allele,
which can be cut with the appropriate restriction en-
zyme, whereas the mutant allele remains uncut in this
assay (fig. 3). We did not find any hints of LOH at the
NF1 gene region in the other neurofibroma from this
patient (NF56-1).
The plexiform neurofibroma NF284-1 revealed allelic
loss for the wild-type allele, which was shown by PCR
amplification of the genomic region of the NF1 gene
encompassing exon 28. Although blood and fibroblast-
like cell cultures from the tumor exhibited two PCR
products with the same intensity (wild-type allele and
allele with the 14-bp duplication, which is the consti-
tutional mutation of patient NF284), the signal repre-
senting the mutant allele was at least five times stronger
than the signal corresponding to the wild-type allele
when we used DNA directly prepared from the tumor
tissue (data not shown). A reduction of messengers com-
ing from the wild-type allele was also detectable in the
tumor when RT-PCR was applied. This result implies
that the fibroblast-like cells are not the primary affected
cells in neurofibromas. Unfortunately, patient NF284
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Figure 3 Agarose gel electrophoresis of TaqI-digested PCR-products derived from patient NF56. The genomic region of the NF1 gene
harboring the constitutional mutation of patient NF56 was amplified with primers PI8H and PI9R. The wild-type allele can be completely
digested, as shown in the control lane (C), the product from the mutant allele remains uncut. Although both products are visible with equal
intensities in blood and tumor 1, tumor 2 reveals a stronger signal of the mutant allele, indicating loss of the wild-type allele in a portion of
the tumor tissue. The difference in migration patterns between the length marker and PCR products is caused by the restriction buffer present
in the samples.
was uninformative with all other intragenic markers
tested, so that the extent of allelic loss remains unclear.
D17S33, which locates proximal to the NF1 gene in the
tumor’s DNA, retained heterozygosity, whereas the dis-
tal marker Mfd15 was not informative. The patient’s
state of homozygosity at eight of the nine markers tested
can be considered as unusual. The reason for this re-
mains unclear, since we do not have detailed information
about the family history of the patient.
Discussion
In this study, seven neurofibromas from four different
NF1 patients were analyzed with a mutation-screening
approach to search for somatic inactivation of the NF1
gene. To our knowledge, this is the first report of an
unbiased search for somatic inactivation of theNF1 gene
to determine the mutational spectrum and the frequency
of second hits in neurofibromas. Seven aberrant peptides
were identified by PTT, most of them deriving from
cDNA fragments located in the GAP-related domain.We
identified previously unknown constitutional mutations
in two of our patients and three tumor-specific somatic
mutations in our sample of neurofibromas. Four of these
NF1 variations are novel lesions (Human Gene Muta-
tion Database Cardiff), whereas one of the tumor-spe-
cific mutations (R1362X) has been reported previously
to occur in the germline of an NF1 patient (Upadhyaya
et al. 1997). Interestingly, all three somatic mutations
were CrT transitions, in a CpG- or CpApG-sequence
context, indicating that the deamination of methylated
cytosine residues may be one of the causes of the somatic
mutations detected in neurofibromas. This may be true
for all three mutations, since Woodcock et al. (1988)
showed that not only CpG dinucleotides but also
CpApG or CpTpG sequences are targets for cytosine
methylation. Moreover, Andrews et al. (1996) directly
showed that neurofibromin gene sequences are indeed
methylated; at least in DNA derived from placenta and
sperm, DNA methylation was almost exclusively re-
stricted to CpG dinucleotides.
In PTT-negative neurofibromas we were able to de-
scribe allelic loss of the wild-type allele in two of three
cases. Both tumors seem to harbor large genomic rear-
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rangements. These may be deletions encompassing the
whole NF1 gene as well as flanking sequences. Alter-
natively, the elimination of the wild-type allele may be
the result of somatic homologous recombination. Both
mechanisms can act upon the NF1 gene, as has been
shown by Stephens et al. (1998). The authors found both
interstitial deletions or isodisomy of 17q regions when
they analyzed leukemic cells from children with NF1.
Taken together, three point mutations and two LOH
events have been detected among seven neurofibromas.
This accounts for a detection rate of 70% for somatic
inactivation of the NF1 gene. If we assume that the two
screening methods applied can not uncover all possible
mutations, like missense mutations, and that the power
of the LOH approach is limited by the frequency of
heterozygous genotypes of the polymorphisms em-
ployed, this rate seems to fit very well with the success
rate described for the analysis of constitutionalNF1mu-
tations (Park and Pivnick 1998; Fahsold et al. 1999).
Neurofibromas consist of a number of different cell
types, and most of them exhibit a polyclonal X-inacti-
vation pattern (Da¨schner et al. 1997). Therefore, it seems
likely that only a subpopulation of cells from the tumors
harbor the somatic mutation, as has been shown else-
where by Sawada et al. (1996). Our data support this
hypothesis, because we never found a complete disap-
pearance of alleles in the LOH experiments; rather, the
signals generated from the diminished alleles were about
half as intense as those of the other alleles. In addition,
fibroblast-like cells cultured from neurofibroma NF284-
1 did not show the somatic mutation found within the
tumor tissue analyzed without prior culturing. These re-
sults demonstrate that fibroblast-like cells are not af-
fected by the second hit and therefore are not the cell
type responsible for tumor growth, confirming the ob-
servation of Kluwe et al. (1999), who showed LOH in
Schwann cell cultures raised from a neurofibroma of a
NF1 patient but not in fibroblast-like cells.
It has been suggested that mRNA editing may have
some impact on tumorigenesis of NF1 (Cappione et al.
1997). These authors have described a slightly increased
level of mRNA editing, at position 3916CrU of theNF1
cDNA, in tumors of NF1 patients, compared with non-
tumor tissue. This posttranscriptional modification leads
to a premature termination codon in the respective
mRNA and may result in expression of a truncated form
of neurofibromin. Later studies of the same group re-
vealed that this phenomenon is not a common feature
of all tumors investigated (Skuse and Cappione 1997).
All of the truncated peptides that we identified in our
neurofibromas were caused by other mutations than the
CrU exchange described by Cappione et al. We did not
observe any conspicuous peptide pattern that would in-
dicate a higher level of mRNA editing in the tumor sam-
ples compared to control cells.
Our results suggest that somatic mutation of the NF1
gene is a general event in neurofibromas of NF1 patients.
Although the number of identified mutations is relatively
small, it seems likely that small subtle mutations occur
with similar frequency to that of LOH in patients’ tu-
mors (three point mutations vs. two instances of LOH).
All of the small mutations found in this study seem to
cluster in the GRD of the NF1 gene. However, because
of the small sample size and the fact that all mutations
are stop mutations, we believe that the apparent clus-
tering may well have occurred by chance and does not
point to a mutation-cluster region like that described for
the APC gene, where 60% of somatic mutations are
located in a narrow region of the gene (Be´roud and
Soussi 1996).
Despite the heterogeneous cell composition of neu-
rofibromas, screening for somatic mutations is possible
with the experimental approach described, and more-
extensive studies using multiple neurofibromas from in-
dividual NF1 patients seem necessary to increase our
knowledge about the somatic mutational spectrum in
neurofibromas. It seems recommendable to include so-
matic mutations identified in neurofibromas in the NF1
database. These future studies may contribute to the
unraveling of at least some features of variable expres-
sivity in NF1. NF1 patients suffering from severe man-
ifestation with several hundreds of neurofibromas
should be studied for possible recurrence of the same
mutation in neighboring tumors. If this is not the case,
a possible involvement of genetically variant repair en-
zymes should be taken into account as modifiers for the
NF1 phenotype.
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